SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 76

Pages Range: 952-953

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Novartis AG

Switzerland (CH) University of Texas Southwestern Medical Center (UT Southwestern)

United States (USA) (US) Swedish Medical Center

United States (USA) (US) Monash University

Australia (AU) Barts Health NHS Trust

United Kingdom (GB) UC San Diego School of Medicine

United States (USA) (US) Hasselt University / Universiteit Hasselt

Belgium (BE)

How to cite

APA:

Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2017). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL. (pp. 952-953).

MLA:

Mease, P. J., et al. "SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL." 2017. 952-953.

BibTeX: Download